Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy.

Thus, when the alemtuzumab treatment is unsuccessful, the authors recommend testing T- and B-cell levels and proceeding with an early switch to ocrelizumab if high B-cell counts are found.